Gastrointestinal toxicity with Celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and reumatoid arthritis: The CLASS study: A randomized controlled trial

Journal of the American Medical Association

Volumn 284, Issue 10, 2000, Pages 1247-1255

  Silverstein, Fred E ^b   Faich, Gerald ^c   Goldstein, Jay L ^d   Simon, Lee S ^e   Pincus, Theodore ^f   Whelton, Andrew ^g   Makuch, Robert ^h   Eisen, Glenn ^f   Agrawal, Naurang M ⁱ   Stenson, William F ^j   Burr, Aimee M ^a   Zhao, William W ^a   Kent, Jeffrey D ^a   Lefkowith, James B ^a   Verburg, Kenneth M ^a   Geis, G Steven ^a  

^a PFIZER INC   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c Pharmaceutical Safety Assessments Inc   (United States)

^d UNIVERSITY OF ILLINOIS   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

^f VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h YALE UNIVERSITY   (United States)

ⁱ DUKE UNIVERSITY   (United States)

^j WASHINGTON UNIVERSITY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; GLUCOCORTICOID; IBUPROFEN; NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; AGED; ARTHRITIS; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIGESTIVE SYSTEM ULCER; DOUBLE BLIND PROCEDURE; DRUG INDUCED DISEASE; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; OSTEOARTHRITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; TREATMENT OUTCOME;

EID: 0034644396     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.284.10.1247     Document Type: Article

References (39)

1. Preference for nonsteroidal anti-inflammatory drugs over acetaminophen by rheumatic disease patients: A survey of 1799 patients with osteoarthritis, rheu matoid arthritis, and fibromyalgia
2. Preference for nonsteroidal anti-inflammatory drugs versus acetaminophen and concomitant use of both types of drugs in patients with osteoarthritis
3. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs: A metaanalysis
4. Variability in risk of gastrointestinal complications with individual nonsteroidal anti-inflammatory drugs: Results of a collaborative meta-analysis
5. Nonsteroidal anti-inflammatory drug use and increased risk for peptic ulcer disease in elderly persons
6. Risks of bleeding peptic ulcer associated with individual nonsteroidal anti-inflammatory drugs
7. Association of upper gastrointestinal toxicity of nonsteroidal anti-inflammatory drugs with continued exposure Cohort study
8. Nonsteroidal anti-inflammatory drugs and the incidence of hospitalizations for peptic ulcer disease in elderly persons
9. Gastrointestinal toxicity of nonsteroidal anti-inflammatory drugs
10. Individual nonsteroidal anti-inflammatory drugs and other risk factors for upper gastrointestinal bleeding and perforation
11. NSAID-induced gastrointestinal complications: The ARAMIS perspective - 1997: Arthritis, Rheumatism, and Aging Medical Information System
12. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs: A randomized, double-blind, placebo-controlled trial
13. FDA arthritis advisory committee meeting: Serious gastrointestinal toxicity of nonsteroidal anti-inflammatory drugs; drug-containing renal and biliary stones; diclofenac and carprofen approved
14. Reduced risk of upper gastrointestinal ulcer complications with celecoxib, a novel COX-2 inhibitor
15. Inhibition of prostaglandin synthesis as a mechanism of action for the aspirin-like drugs
16. Basic biology and clinical application of specific cyclooxygenase-2 inhibitots
17. Kinetic basis for selective inhibition of cyclooxygenases
18. Expression and selective inhibition of the constitutive and inducible forms of human cyclooxygenase
19. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: A randomized controlled trial
20. Treatment of osteoarthritis with celecoxib, a cyclooxygenase-2 inhibitor: A randomized controlled trial
21. Nonsteroidal anti-inflammatory drugs
22. Physician advice and individual behaviors about cardiovascular disease risk reduction - Seven states and Puerto Rico, 1997
23. Gastrointestinal bleeding during low-dose aspirin administration for prevention of arterial occlusive events: A critical analysis
24. Gastrointestinal complications of prescription and over-the-counter nonsteroidal anti-inflammatory drugs: A view from the ARAMIS database
25. The gastrointestinal toxicity of aspirin: An overview of randomised controlled trials
26. Prophylactic aspirin and risk of peptic ulcer bleeding
27. Risk of aspirin-associated major upper-gastrointestinal bleeding with enteric-coated or buffered product
28. Risk of upper gastrointestinal bleeding and perforation associated with individual nonsteroidal anti-inflammatory drugs
29. Peptic ulcer and gastrointestinal hemorrhage associated with nonsteroidal anti-inflammatory drug use in patients younger than 65 years: A large health maintenance organization cohort study
30. Nonsteroidal anti-inflammatory drugs and upper gastrointestinal bleeding: Identifying high-risk groups by excess risk estimates
31. Risk of hospitalization for upper gastrointestinal tract bleeding associated with ketorolac, other nonsteroidal anti-inflammatory drugs, calcium antagonists, and other antihypertensive drugs
32. Influence of H pylori (Hp) infection and/or low dose aspirin (ASA) on gastroduodenal ulceration in patients treated with placebo, celecoxib or NSAIDs
33. Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: Randomised double-blind comparison
34. Nephrotoxicity of nonsteroidal anti-inflammatory drugs: Physiologic foundations and clinical implications
35. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: The human pharmacology of a selective inhibitor of COX-2
36. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States
37. COX-2 specific inhibitors: Definition of a new therapeutic concept